DE60333500D1 - Verfahren zur Identifizierung antigener Peptide - Google Patents

Verfahren zur Identifizierung antigener Peptide

Info

Publication number
DE60333500D1
DE60333500D1 DE60333500T DE60333500T DE60333500D1 DE 60333500 D1 DE60333500 D1 DE 60333500D1 DE 60333500 T DE60333500 T DE 60333500T DE 60333500 T DE60333500 T DE 60333500T DE 60333500 D1 DE60333500 D1 DE 60333500D1
Authority
DE
Germany
Prior art keywords
methods
antigenic peptides
utilized
sequence
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60333500T
Other languages
English (en)
Inventor
Harald Kropshofer
Anne Vogt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE60333500D1 publication Critical patent/DE60333500D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Reproductive Health (AREA)
DE60333500T 2002-10-02 2003-09-24 Verfahren zur Identifizierung antigener Peptide Expired - Lifetime DE60333500D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02022223 2002-10-02

Publications (1)

Publication Number Publication Date
DE60333500D1 true DE60333500D1 (de) 2010-09-02

Family

ID=32116218

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60320196T Expired - Lifetime DE60320196T2 (de) 2002-10-02 2003-09-24 Verfahren zur Identifizierung antigener Peptide
DE60333500T Expired - Lifetime DE60333500D1 (de) 2002-10-02 2003-09-24 Verfahren zur Identifizierung antigener Peptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60320196T Expired - Lifetime DE60320196T2 (de) 2002-10-02 2003-09-24 Verfahren zur Identifizierung antigener Peptide

Country Status (8)

Country Link
US (1) US20040086521A1 (de)
EP (3) EP1405862B1 (de)
JP (3) JP4620339B2 (de)
AT (2) ATE474851T1 (de)
AU (1) AU2003248438A1 (de)
CA (1) CA2441690C (de)
DE (2) DE60320196T2 (de)
ES (1) ES2346574T3 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE442377T1 (de) * 2003-08-07 2009-09-15 Hoffmann La Roche Ra antigene peptide
EP1715343B1 (de) 2005-04-20 2009-12-09 F. Hoffmann-La Roche Ag Verfahren zur Identifizierung von Epitopen in Zusammenhang mit Immunogenität bei Biopharmazeutika
ES2334936T3 (es) * 2005-04-20 2010-03-17 F. Hoffmann-La Roche Ag Metodo de identificacion de epitopos relacionados con la inmunogenicidad en biofarmacos.
JPWO2007055283A1 (ja) * 2005-11-10 2009-04-30 Jsr株式会社 核内受容体タンパク質複合体のプロテオミクス解析方法
US20100086938A1 (en) * 2006-11-29 2010-04-08 Takashi Shimada Mass spectrometry of biological sample using immunoprecipitation
ES2663662T3 (es) * 2008-01-18 2018-04-16 President And Fellows Of Harvard College Métodos para detectar distintivos de enfermedades o afecciones en fluidos corporales
JP5823379B2 (ja) * 2009-05-29 2015-11-25 ノバルティス アーゲー インフルエンザウイルスヘマグルチニンについてのアッセイ
WO2012012717A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
US20130184178A1 (en) 2010-07-23 2013-07-18 President And Fellows Of Harvard College Methods of Detecting Autoimmune or Immune-Related Diseases or Conditions
WO2013150680A1 (ja) * 2012-04-06 2013-10-10 独立行政法人産業技術総合研究所 プロテインタグ、タグ化タンパク質及びタンパク質精製方法
WO2014164366A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting cancer
EP3152574A4 (de) * 2014-06-06 2017-12-06 Singapore Health Services Pte Ltd Verfahren zur verwendung von zellen in zusammenhang mit einer autoimmunkrankheit
KR101831483B1 (ko) 2014-06-17 2018-02-23 이화여자대학교 산학협력단 Mhc-페리틴 결합체, 이를 포함하는 나노파티클 및 이의 용도
US10718781B2 (en) 2014-07-14 2020-07-21 Chugai Seiyaku Kabushiki Kaisha Method for identifying epitope on protein
WO2016079143A1 (de) 2014-11-17 2016-05-26 Pharis Biotec Gmbh Inhibitor der viralen hepatitis c infektion
CN105928771B (zh) * 2016-04-08 2019-01-18 西藏恒久投资有限公司 一种检测疫苗抗原含量的样品前处理方法
CN110118845A (zh) * 2018-02-06 2019-08-13 北京金则医学科技发展有限公司 检测多种氨基酸和酰基肉碱、甲基丙二酸的方法和试剂盒
JP6712369B2 (ja) * 2018-05-29 2020-06-24 株式会社森永生科学研究所 抗ペプチド抗体の製造方法及び設計方法
US11603565B2 (en) * 2018-06-15 2023-03-14 Roche Sequencing Solutions, Inc. System for identification of antigens recognized by T cell receptors expressed on tumor infiltrating lymphocytes
WO2020037046A1 (en) * 2018-08-14 2020-02-20 Board Of Regents, The University Of Texas System Single molecule sequencing peptides bound to the major histocompatibility complex
CN113167796A (zh) * 2018-09-11 2021-07-23 朱诺治疗学股份有限公司 对工程化细胞组合物进行质谱分析的方法
JP2021047198A (ja) * 2020-12-04 2021-03-25 Ｋａｒｙｄｏ ＴｈｅｒａｐｅｕｔｉＸ株式会社 心筋梗塞、認知症、および腫瘍からなる群から選択される一種を予防、または治療するための有効成分の候補物質のスクリーニング装置、スクリーニングプログラム、およびスクリーニング方法
CN113406240B (zh) * 2021-07-02 2023-03-24 杭州艾儿默细胞生物科技有限公司 检测pHLA复合物中抗原肽的超滤-高效液相色谱法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
WO2000005249A2 (en) * 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
EP1098902A4 (de) * 1998-07-23 2002-07-24 Yeda Res & Dev Behandlung von autoimmunkrankheiten mittels copolymer 1 und ähnlichen copolymeren und peptiden
WO2002040647A1 (en) * 2000-11-14 2002-05-23 U.S. Army Medical Research Institute Of Infectious Diseases Method of establishing cultures of human dendritic cells and use thereof

Also Published As

Publication number Publication date
JP2011012073A (ja) 2011-01-20
EP1826217A1 (de) 2007-08-29
EP1714981A3 (de) 2006-12-20
EP1405862A3 (de) 2004-06-09
JP2004123749A (ja) 2004-04-22
EP1405862A2 (de) 2004-04-07
EP1714981A2 (de) 2006-10-25
DE60320196T2 (de) 2009-05-14
CA2441690C (en) 2011-08-02
US20040086521A1 (en) 2004-05-06
AU2003248438A1 (en) 2004-04-22
CA2441690A1 (en) 2004-04-02
EP1826217B1 (de) 2010-07-21
DE60320196D1 (de) 2008-05-21
JP4620339B2 (ja) 2011-01-26
EP1405862B1 (de) 2008-04-09
ES2346574T3 (es) 2010-10-18
ATE391723T1 (de) 2008-04-15
ATE474851T1 (de) 2010-08-15
JP2007211020A (ja) 2007-08-23

Similar Documents

Publication Publication Date Title
DE60320196D1 (de) Verfahren zur Identifizierung antigener Peptide
ES2836273T3 (es) Método para el tratamiento del cáncer
KR102447139B1 (ko) 종양 특이적 신생항원을 확인하는 조성물 및 방법
US10550430B2 (en) Method and kit for determining whether a subject shows an immune response
WO2003106692A3 (en) METHODS OF IDENTIFYING ALLO-ANTIGENS AND THEIR USE IN CANCER THERAPY AND TRANSPLANTATION
ES2537323T3 (es) Péptido CDCA1 y agente farmacéutico que lo comprende
EP3004137B1 (de) Verbessertes verfahren zur detektion, zubereitung und abreicherung von cd4+ t lymphozyten
CA3049456A1 (en) Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
DK1759013T3 (da) Identificering af overflade-associerede antigener til tumordiagnose
US20170146526A1 (en) Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs
CA2715536A1 (en) Cd4+ t-cells with cytolytic properties
CN113015542A (zh) 具有改善的氧化还原酶基序的免疫原性肽
JP2021534830A (ja) 腫瘍特異的抗原を特定するためのプロテオゲノミクスに基づいた方法
Beckhove et al. Rapid T cell–based identification of human tumor tissue antigens by automated two-dimensional protein fractionation
US20230098624A1 (en) Methods and vaccines for inducing immune responses to multiple different mhc molecules
WO2006102901A3 (en) Immunogenic egfr peptides comprising foreign t cell stimulating epitope
JP2009500036A (ja) 非ゼロバックグラウンドのペプチドによる免疫応答レベルの安定な定量化及び検出
ES2353964T3 (es) Procedimiento para la inmunoterapia de tumores.
JP2022532409A (ja) 改変されたシステインを含む酸化還元酵素モチーフを有する免疫原性ペプチド
Scheibenbogen et al. Long‐term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides
JPWO2005105993A1 (ja) Ｈｌａ結合性ペプチド、その前駆体、それをコードするｄｎａ断片および組み換えベクター
EP3600401A1 (de) Rekombinante chlamydia-aktivierte b-zellplattformen und anwendungsverfahren dafür
RU2650872C1 (ru) Искусственный ген MEL-TCI, кодирующий полиэпитопный белок-иммуноген MEL-TCI, рекомбинантная плазмидная ДНК pMEL-TCI, обеспечивающая экспрессию искусственного гена MEL-TCI и искусственный белок-иммуноген MEL-TCI, содержащий CTL- и Th-эпитопы антигенов меланомы, рестриктированные множественными аллелями HLA I и II класса
NAIM Gold-nanocluster-mediated microinflammation detection using a tissue clearing method and Molecular mechanism for SARS-CoV-2-specific CD4+ T cell activation in healthy people
RU2005100758A (ru) Способ картирования и устранения эпитопов т-клеток